Abstract Library

#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors

Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.

Conference:

Presenting Author:

Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,

Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,

#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors

Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Sasano H

Authors: Iida S, Miki Y, Ono K, Sasano H,

Keywords: neuroendocrine tumors, mTOR inhibitors, MEK inhibitors, combination therapy,